Pricing Log in Create free account

InflaRx N.V. (IFRX) vs SAB Biotherapeutics, Inc. (SABS)

InflaRx N.V. and SAB Biotherapeutics, Inc. are both Biotechnology companies. SAB Biotherapeutics, Inc. is the larger, with a market value of $235.7M against $212.2M — 1.1× the size. SAB Biotherapeutics, Inc. grew revenue faster over the last twelve months: −60.3% against −83.4%. Across the 15 metrics below, SAB Biotherapeutics, Inc. leads on 8 and InflaRx N.V. on 7.

Valuation

Metric IFRX SABS Biotechnology median
P/E n/m n/m 8.50
P/S 5,075.70 123.99 9.71
P/B 0.91 0.94 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.71 n/m 0.64
EV/Sales (1,061.22) 62.79 9.21
Earnings yield (43.94%) (25.30%) (33.15%)
Free cash flow yield (17.60%) (28.47%) (25.50%)

Profitability

Metric IFRX SABS Biotechnology median
Gross margin (26,762.42%) 100.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (38.71%) (19.21%) (56.36%)
Return on assets (32.75%) (16.24%) (48.04%)
Return on invested capital 0.00% (38.97%) 0.00%

Growth

Metric IFRX SABS Biotechnology median
Revenue growth (TTM) (83.39%) (60.26%) 6.02%
EPS growth (last fiscal year) 9.41% 78.53% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% (26.69%) 0.00%

Health

Metric IFRX SABS Biotechnology median
Debt to equity 0.00 0.01 0.00
Current ratio 8.22 9.22 4.72
Net debt to EBITDA 0.97 2.03 0.96

Dividend

Metric IFRX SABS Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric IFRX SABS Biotechnology median
Market cap 212.21m 235.66m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack